[Skip to Navigation]
March 1964

S35-Labeled Bendroflumethiazide in Human Beings: Clinical Studies

Author Affiliations


From the Department of Medicine, University of Colorado School of Medicine.

Arch Intern Med. 1964;113(3):373-377. doi:10.1001/archinte.1964.00280090059010

Bendroflumethiazide (Naturetin)-3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide —is a nonmercurial diuretic agent of the benzothiadiazine group, which is effective clinically in the treatment of edema and hypertension.1-5 We have previously studied 6,7 the renal excretion of chlorothiazide and hydrochlorothiazide labeled with radioactive carbon (C14) in normal subjects and in patients with various medical diseases associated with the retention of water and electrolytes. The cumulative renal excretion of radioactivity was lower in patients with cardiac, renal, and hepatic diseases than in normal subjects. The amount of radioactivity recovered in the urine appeared to be inversely proportional to the severity of the disease.

In the present study, S35-labeled bendroflumethiazide was administered orally or intravenously to normal subjects and patients with cardiac, renal, and hepatic diseases. The cumulative renal excretion of radioactivity was compared with that of chlorothiazide and hydrochlorothiazide.

Material and Methods 

Material.  —A total of 23 studies were performed in

Add or change institution